Fourier Intelligence Secures RMB 30 Million Series A Funding Led by Jingxu Venture Capital

VCBeat (WeChat ID: vcbeat) has learnedOn February 26, 2018, Fourier Intelligence, a leading Chinese rehabilitation robotics company, announced the completion of its RMB 30 million Series A financing round. The round was led by Jingxu Venture Capital, with participation from Qianhai Fund of Funds, while existing investors IDG Capital and Volcanic Stone Capital continued to participate.

Shanghai Fourier Intelligence Co., Ltd. was established in July 2015 and is located in the core area of Zhangjiang, Shanghai. The company is primarily dedicated to the research, development, and industrialization of intelligent robots, possessing multiple independently developed core technologies and products.

The company secured angel investment from top-tier international venture capital firms IDG Capital and Shanghai Zhangjiang Sci-Tech Investment, and in 2016, it again raised tens of millions of RMB in Pre-A financing from Volcanic Stone Capital. The company’s core R&D team consists of industry-leading robotics experts and medical specialists, and it has established project collaborations with multiple universities and Grade A tertiary hospitals.

In early 2017, Fourier Intelligence launched China’s first commercialized lower-limb exoskeleton rehabilitation robot, the Fourier X1. The medical version is designed for rehabilitation training in hospitals, while the personal version assists with walking, enabling paralyzed patients to break free from wheelchairs, regain their ability to walk, and return to normal life.

Meanwhile, the company has also launched Fourier M2, its first haptic-enabled upper-limb rehabilitation robot. Built on core technologies such as force feedback, the M2 can precisely simulate a variety of real-life mechanical scenarios, providing users with diverse goal-oriented training to stimulate brain functional reorganization and thereby restore upper-limb function.Currently, this device is also the first rehabilitation robot product from China to enter the European market, marking a milestone for domestically produced rehabilitation robots.

Fourier M2 Enters Top European Rehabilitation Centers

Exoskeleton rehabilitation robots are a symbol of national scientific and technological strength. According to the industry report on rehabilitation center robots released by WinterGreen Research, the global market for rehabilitation robots will exceed $1.8 billion by 2020.

It is reported that this round of financing,Fourier Intelligence will continue to deepen its R&D in the field of medical robotics, accelerate commercialization, and build an ecosystem centered on rehabilitation robotics technology, building upon its Fourier X1 and Fourier M2 product lines.

Jingxu Venture Capital is a venture capital firm focused on the healthcare sector. With a professional investment team and robust capabilities in industry resource integration, it is committed to value investing by identifying high-quality enterprises across the healthcare industry chain and facilitating their rapid growth.

Since its inception, Jingxu Venture Capital has continuously refined its investment portfolio in niche sectors such as innovative medical devices, chain healthcare services, and biopharmaceuticals. To date, it has completed investments in more than 20 high-growth healthcare companies, including: Bowei Biologics and Antegenes in the biopharmaceutical sector; Lainuo Medical, Jinshi Biotechnology, and BioNano in the innovative medical device sector; and Youmu Dental (NEEQ: 870486), China Cord Blood Corporation (NYSE: CO), and Jiahui Health (NEEQ: 835660) in the healthcare services sector.

Qianhai Equity Investment Fund (Limited Partnership), abbreviated as “Qianhai FoF,” is currently a leading equity investment fund of funds in China. With a total fund size of RMB 28.5 billion, it is the largest commercially raised fund of funds in China. Established on January 8, 2015, and headquartered in Qianhai, Shenzhen, Qianhai FoF carries the important mission assigned by the State Council’s strategic deployment to build the Qianhai National-Level New Area, marking a milestone in the development of China’s equity investment fund industry.

The Qianhai Fund of Funds has gathered influential and well-resourced investors with substantial strength in China. Investor types include governments at all levels, insurance and financial institutions, renowned enterprises and listed companies, as well as commercially accomplished individuals. The fund’s executive management team is led by Mr. Jin Haitao, a leading figure in the equity investment industry. The institutional partner is Shenzhen Capital Group Co., Ltd., and the joint partners include prominent investors such as Mr. Ma Weihua, Mr. Shen Nanpeng, Mr. Xiong Xiaoge, Mr. Li Wei, and Mr. Ni Zhengdong.